PepFactor
Growth Pipelines
Growth Pipelines
PepFactor SALES PIPELINE

PEPFACTOR COSMETIC SALES
Maximise sales of PepFactor as a cosmetic product in the scalp and skin markets: sales currently US$90k per month

PEPFACTOR DISTRIBUTION
Sales and distrIbution are rapidly expanding.

TRADEMARK REGISTRATIONS
Trademarks have neen submitted

DEVELOPMENT PATENT
Patent for ReGen Factors uniguee development method have been processed

CE MARK
CE Mark to be submitted for registration of PepFactor for sale in the European Union and the UK
PepFactor FDA APPROVAL PIPELINE

FDA CONSULTANTS
FOA consultants have been appointed to navigate the FDA approval process

PRIMARY INVESTIGATOR
A primary investigator for the phase 1 trial has been appointed

TRIAL DESIGN AND PLANNING
Trial design and planning is underway

PRE-IND MEETING
Preparations are being made for a Pre-IND meeting to be held H2 2021

PHASE 1 TRIAL
Phase1 Clinical Trial to Commence 2022